.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Covington
Queensland Health
Cantor Fitzgerald
Citi
Julphar
Novartis
McKinsey
US Army
Dow

Generated: December 12, 2017

DrugPatentWatch Database Preview

Janssen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?

JANSSEN PHARMS has fifty-six approved drugs.

There are thirty-seven US patents protecting JANSSEN PHARMS drugs and there have been four Paragraph IV challenges on JANSSEN PHARMS drugs in the past three years.

There are seven hundred and eighty-one patent family members on JANSSEN PHARMS drugs in fifty-seven countries and seventy-three supplementary protection certificates in fifteen countries.

Summary for Janssen Pharms

International Patents:781
US Patents:37
Tradenames:54
Ingredients:34
NDAs:56
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Janssen PharmsORTHO-NOVUM 7/7/7-28ethinyl estradiol; norethindroneTABLET;ORAL-28018985-002Apr 4, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsDITROPAN XLoxybutynin chlorideTABLET, EXTENDED RELEASE;ORAL020897-001Dec 16, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsRISPERDAL CONSTArisperidoneINJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsINVEGA TRINZApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-001May 18, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsINVOKANAcanagliflozinTABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen PharmsORTHO TRI-CYCLEN LOethinyl estradiol; norgestimateTABLET;ORAL-28021241-001Aug 22, 2002ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-003Aug 8, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsULTRACETacetaminophen; tramadol hydrochlorideTABLET;ORAL021123-001Aug 15, 2001ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-003Dec 8, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen PharmsNIZORALketoconazoleSHAMPOO;TOPICAL019927-001Aug 31, 1990► Subscribe► Subscribe
Janssen PharmsRISPERDALrisperidoneTABLET, ORALLY DISINTEGRATING;ORAL021444-002Apr 2, 2003► Subscribe► Subscribe
Janssen PharmsORTHO TRI-CYCLEN LOethinyl estradiol; norgestimateTABLET;ORAL-28021241-001Aug 22, 2002► Subscribe► Subscribe
Janssen PharmsORTHO-NOVUM 7/7/7-21ethinyl estradiol; norethindroneTABLET;ORAL-21018985-001Apr 4, 1984► Subscribe► Subscribe
Janssen PharmsTOPAMAXtopiramateCAPSULE;ORAL020844-002Oct 26, 1998► Subscribe► Subscribe
Janssen PharmsRISPERDALrisperidoneTABLET, ORALLY DISINTEGRATING;ORAL021444-002Apr 2, 2003► Subscribe► Subscribe
Janssen PharmsDITROPAN XLoxybutynin chlorideTABLET, EXTENDED RELEASE;ORAL020897-001Dec 16, 1998► Subscribe► Subscribe
Janssen PharmsTOPAMAXtopiramateTABLET;ORAL020505-002Dec 24, 1996► Subscribe► Subscribe
Janssen PharmsRISPERDALrisperidoneTABLET, ORALLY DISINTEGRATING;ORAL021444-005Dec 23, 2004► Subscribe► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-002Aug 1, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JANSSEN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
paliperidone palmitateExtended-release Injectable Suspension39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mLINVEGA SUSTENNA11/21/2017
canagliflozinTablets100 mg and 300 mgINVOKANA3/29/2017
canagliflozin andmetforminhydrochlorideTablets50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mgINVOKAMET3/29/2017
rivaroxabanTablets10 mg, 15 mg, and 20 mgXARELTO7/1/2015
itraconazoleOral Solution10 mg/mLSPORANOX5/3/2013
levofloxacinOral Solution25 mg/mLLEVAQUIN7/30/2009
norelgestromin and ethinyl estradiolTransdermal System0.15 mg/0.02 mg per 24 hoursORTHO EVRA3/22/2007
galantamine hydrobromide Extended-release Capsules16 mg and 24 mgRAZADYNE ER3/11/2006
galantamine hydrobromide Extended-release Capsules8 mg RAZADYNE ER3/2/2006
almotriptan malateTablets6.25 mg and 12.5 mgAXERT12/8/2005
topiramateTablets50 mgTOPAMAX9/8/2005
topiramateCapsules15 mg and 25 mgTOPAMAX SPRINKLE9/7/2005
methylphenidate hydrochlorideExtended-release Tablets18 mg*, 27 mg, 36 mg and 54 mgCONCERTA7/19/2005
metformin hydrochlorideExtended-release Tablets18 mg, 27 mg, 36 mg and 54 mgCONCERTA7/19/2005
risperidoneOrally Disintegrating Tablets0.25 mgRISPERDAL4/11/2005
risperidoneOrally Disintegrating Tablets3 mg and 4 mgRISPERDAL3/23/2005
galantamine hydrobromide Tablets4 mg, 8 mg and 12 mgRAZADYNE2/28/2005
topiramateTablets25 mg, 100 mg and 200 mgTOPAMAX12/26/2001

Non-Orange Book Patents for Janssen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,936,810Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
7,816,331Substituted indazole-O-glucosides► Subscribe
7,820,630Substituted indole-O-glucosides► Subscribe
8,822,458Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
7,816,330Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
7,816,328Substituted fused heterocyclic C-glycosides► Subscribe
7,576,111Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
6,110,503 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent► Subscribe
7,935,674Indole derivatives► Subscribe
7,094,763Substituted fused heterocyclic C-glycosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen Pharms Drugs

Country Document Number Estimated Expiration
Japan4130466► Subscribe
Taiwan200529859► Subscribe
Hong Kong1032009► Subscribe
Denmark1845961► Subscribe
Japan5159788► Subscribe
Israel175490► Subscribe
Estonia200200341► Subscribe
Serbia20060323► Subscribe
Taiwan200524950► Subscribe
China1939304► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00140Netherlands► SubscribePRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
80016Netherlands► SubscribePRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
14/029Ireland► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
00152Netherlands► SubscribePRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405
6Finland► Subscribe
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
2011008,C0904081Lithuania► SubscribePRODUCT NAME: PALIPERIDONI PALMITAS; REGISTRATION NO/DATE: EU/1/11/672/001 - EU/1/11/672/006 20110304
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
US Department of Justice
Merck
McKinsey
Queensland Health
Mallinckrodt
Express Scripts
Chinese Patent Office
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot